Marpai Returns to Revenue Growth in Third Quarter 2026, Achieving First Year-Over-Year and Sequential Increase Since 2023
Integrated TPA and
Third Quarter 2026 Highlights
- Revenue increased 9.6% year-over-year from
$4.0 million for the three months endedSeptember 30, 2025 , to$4.4 million for the three months endedSeptember 30, 2026 ; - Operating loss decreased by
$0.3 million from$2.8 million for the three months endedSeptember 30, 2025 , to$2.5 million for the three months endedSeptember 30, 2026 . - Net loss per common share improved by
$0.07 from$(0.20) per share for the three months endedSeptember 30, 2025 , to$(0.13) per share for the three months endedSeptember 30, 2026 . - Closed a
$12.1 million Series A Convertible Preferred Stock financing inJuly 2026 . - Expanded TPA and PBM business development and accelerated AI-powered claims automation.
Management Commentary
"Over the past several quarters, we believe we have fundamentally repositioned
Building Commercial Momentum Across TPA and PBM
"We believe commercial momentum is building across our TPA and PBM businesses, including opportunities with larger employers, and we have strengthened our business development team. Importantly, we believe our ability to offer both TPA and PBM services provides an opportunity to deepen customer relationships, expand our addressable market, and deliver a more comprehensive solution to employers seeking lower healthcare costs and better care for their employees."
AI
"We are also modernizing our claims platform with artificial intelligence and AI agents, which already handle routine provider inquiries such as claim status and eligibility questions. Our goal is a more automated, scalable platform that can support significantly more business without a corresponding increase in administrative expense. Our
Time to Transform Health Care
"Health care is broken, and we all know it. Employers pay more every year, their employees too often get less, and the system runs on a complexity that serves almost everyone except the people it is meant to protect. We think that it is time to get a little crazy. It is time to remember that the people insured are the ones who count, it is time to provide better care, and we believe we can help save lives while saving them money. Some may see that ambition as unrealistic, since we believe that only a few in the industry are doing this. We believe the company willing to challenge how health care works is the one that will end up changing it. In short, it is time to transform the world of health care, and
Third Quarter 2026 Financial Results
Revenue was
Operating loss narrowed to
Nine-Month 2026 Financial Results
For the nine months ended
Series A Financing and Liquidity
On
About
Forward-Looking Statements
This press release contains forward-looking statements, as that term is defined in the Private Litigation Reform Act of 1995, that involve significant risks and uncertainties. Forward-looking statements can be identified through the use of words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "estimates," "guidance," "may," "can," "could", "will", "potential", "should," "goal" and variations of these words or similar expressions. For example, the Company is using forward-looking statements when it discusses statements regarding the Company's belief that commercial momentum is building across its TPA and PBM businesses, including opportunities with larger employers; its belief that its ability to offer both TPA and PBM services provides an opportunity to deepen customer relationships, expand its addressable market, and deliver a more comprehensive solution to employers seeking lower healthcare costs and better care for their employees; the Company's stated goals of a more automated, scalable platform that can support significantly more business without a corresponding increase in administrative expense and moving toward sustainable profitability; its belief that it is time to get a little crazy and that the Company intends to help lead the way to transform the world of health care. Readers are cautioned not to place undue reliance on these forward-looking statements, which reflect
More detailed information about
| | | | | | ||||
| CONDENSED CONSOLIDATED BALANCE SHEETS | | | | | ||||
| (UNAUDITED) | | | | | ||||
| (in thousands, except share and per share data) | | | | | ||||
| | | | | | | | | |
| | | | | | | | | |
| ASSETS: | | | | | | | | |
| Current assets: | | | | | | | | |
| Cash and cash equivalents | | $ 360 | | $ 133 | | | | |
| Restricted cash | | 7,411 | | 8,818 | | | | |
| Accounts receivable, net of allowance for credit losses of | | 940 | | 697 | | | | |
| Unbilled receivables | | 1,313 | | 280 | | | | |
| Prepaid expenses and other current assets | | 347 | | 408 | | | | |
| Total current assets | | 10,371 | | 10,336 | | | | |
| | | | | | | | | |
| Capitalized software, net | | — | | 60 | | | | |
| Operating lease right-of-use assets | | 179 | | 218 | | | | |
| Security deposits | | 227 | | 229 | | | | |
| Other long-term asset | | 35 | | 61 | | | | |
| Total assets | | $ 10,812 | | $ 10,904 | | | | |
| LIABILITIES AND STOCKHOLDERS' DEFICIT | | | | | | | | |
| Current liabilities: | | | | | | | | |
| Accounts payable | | $ 2,691 | | $ 3,668 | | | | |
| Accrued expenses | | 1,606 | | 2,115 | | | | |
| Accrued fiduciary obligations | | 7,238 | | 8,521 | | | | |
| Deferred revenue | | 72 | | 89 | | | | |
| Current portion of operating lease liabilities | | 284 | | 264 | | | | |
| Current portion of convertible debentures, net | | 1,966 | | 3,037 | | | | |
| Other short-term liabilities | | — | | 8,000 | | | | |
| Vendor financing advance | | 2,000 | | — | | | | |
| Total current liabilities | | 15,857 | | 25,694 | | | | |
| | | | | | | | | |
| Other long-term liabilities | | 18,788 | | 11,450 | | | | |
| Convertible debentures, net of current portion | | 5,620 | | 5,795 | | | | |
| Operating lease liabilities, net of current portion | | 313 | | 528 | | | | |
| Total liabilities | | 40,578 | | 43,467 | | | | |
| COMMITMENTS AND CONTINGENCIES | | | | | | | | |
| STOCKHOLDERS' DEFICIT | | | | | | | | |
| Preferred stock, | | — | | — | | | | |
| Common stock, | | 3 | | 2 | | | | |
| Additional paid-in capital | | 96,677 | | 82,829 | | | | |
| Accumulated deficit | | (126,446) | | (115,394) | | | | |
| Total stockholders' deficit | | (29,766) | | (32,563) | | | | |
| Total liabilities and stockholders' deficit | | $ 10,812 | | $ 10,904 | | | | |
| | | | | | | | | |
| | | | | | | | | |
| | | $ — | | $ — | | | | |
| | | | | | | | | |
| | | | | | | | | |
| | ||||||||
| CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS | ||||||||
| (UNAUDITED) | ||||||||
| (in thousands, except share and per share data) | ||||||||
| | | Three Months Ended | | Nine Months Ended | ||||
| | | | | | | | | |
| Revenue (including related party amounts of | | $ 4,424 | | $ 4,037 | | $ 13,034 | | $ 14,111 |
| Costs and expenses | | | | | | | | |
| Cost of revenue (exclusive of depreciation and amortization | | 3,400 | | 2,963 | | 9,808 | | 10,357 |
| General and administrative | | 2,136 | | 2,067 | | 7,335 | | 6,833 |
| Information technology | | 1,129 | | 1,245 | | 3,395 | | 3,927 |
| Sales and marketing | | 149 | | 295 | | 514 | | 851 |
| Research and development | | — | | — | | — | | 7 |
| Depreciation and amortization | | — | | 107 | | 60 | | 321 |
| Facilities | | 116 | | 131 | | 345 | | 442 |
| Total costs and expenses | | 6,930 | | 6,808 | | 21,457 | | 22,738 |
| Operating loss | | (2,506) | | (2,771) | | (8,423) | | (8,627) |
| Other income (expenses) | | | | | | | | |
| Other income, net | | 77 | | 74 | | 230 | | 123 |
| Interest expense, net | | (857) | | (797) | | (2,859) | | (2,430) |
| Loss before provision for income taxes | | (3,286) | | (3,494) | | (11,052) | | (10,934) |
| Income tax expense | | — | | — | | — | | — |
| Net loss | | $ (3,286) | | $ (3,494) | | $ (11,052) | | $ (10,934) |
| Cumulative preferred stock dividends | | $ (162) | | $ — | | $ (162) | | $ — |
| Net loss attributable to common stockholders | | $ (3,448) | | $ (3,494) | | $ (11,214) | | $ (10,934) |
| Net loss per share attributable to common stockholders, basic & fully diluted | | $ (0.13) | | $ (0.20) | | $ (0.43) | | $ (0.69) |
| Weighted average common shares outstanding, basic and | | 26,829,700 | | 17,299,687 | | 25,799,051 | | 15,868,157 |
| | | | | | | | | |
| | | | | | | | | |
| | | | | | | | | |
| | | | | | | | | |
| | | | | | ||||
| CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS | | | | | ||||
| (UNAUDITED) | | | | | ||||
| (in thousands) | | | | | ||||
| | | Nine Months Ended | | | | | ||
| | | | | | | | | |
| Cash flows from operating activities: | | | | | | | | |
| Net loss | | $ (11,052) | | $ (10,934) | | | | |
| Adjustments to reconcile net loss to net cash used in operating activities: | | | | | | | | |
| Depreciation and amortization | | 60 | | 321 | | | | |
| Share-based compensation | | 1,252 | | 1,458 | | | | |
| Shares issued to vendors in exchange for services | | 55 | | 1,008 | | | | |
| Amortization of right-of-use asset | | 39 | | 45 | | | | |
| Non-cash interest expense | | 1,813 | | 1,362 | | | | |
| Amortization of debt premium and debt issuance costs, net | | 154 | | (25) | | | | |
| Bad debt expense | | 217 | | — | | | | |
| Changes in operating assets and liabilities: | | | | | | | | |
| Accounts receivable and unbilled receivables | | (1,493) | | 236 | | | | |
| Prepaid expense and other assets | | 89 | | 306 | | | | |
| Accounts payable | | (977) | | 1,302 | | | | |
| Accrued expenses | | (195) | | (603) | | | | |
| Accrued fiduciary obligations | | (1,283) | | 3,019 | | | | |
| Operating lease liabilities | | (195) | | (183) | | | | |
| Other liabilities | | (41) | | (2) | | | | |
| Net cash used in operating activities | | (11,557) | | (2,690) | | | | |
| Cash flows from investing activities: | | | | | | | | |
| Proceeds from sale of business unit | | — | | 500 | | | | |
| Net cash provided by investing activities | | — | | 500 | | | | |
| Cash flows from financing activities: | | | | | | | | |
| Proceeds from issuance of related party promissory notes | | 660 | | — | | | | |
| Payments on related party promissory notes | | (660) | | — | | | | |
| Proceeds from vendor financing advance | | 2,000 | | — | | | | |
| Proceeds from related party advance | | 1,000 | | — | | | | |
| Payments for related party advance | | (1,000) | | — | | | | |
| Proceeds from issuance of convertible debentures | | — | | 3,000 | | | | |
| Payments of convertible debenture issuance costs | | — | | (162) | | | | |
| Payments on convertible debentures | | (1,250) | | (2,000) | | | | |
| Payments to seller for acquisition | | (2,450) | | (196) | | | | |
| Proceeds from issuance of common stock in a private offering, net | | — | | 2,831 | | | | |
| Proceeds from issuance of preferred stock in a private offering, net | | 12,077 | | — | | | | |
| Net cash provided by financing activities | | 10,377 | | 3,473 | | | | |
| | | | | | | | | |
| Net (decrease) increase in cash, cash equivalents and restricted cash | | (1,180) | | 1,283 | | | | |
| | | | | | | | | |
| Cash, cash equivalents and restricted cash at beginning of period | | 8,951 | | 9,232 | | | | |
| Cash, cash equivalents and restricted cash at end of period | | $ 7,771 | | $ 10,515 | | | | |
| | | | | | | | | |
| Reconciliation of cash, cash equivalents, and restricted cash reported in | | | | | | | | |
| Cash and cash equivalents | | $ 360 | | $ 445 | | | | |
| Restricted cash | | 7,411 | | 10,070 | | | | |
| Total cash, cash equivalents and restricted cash shown in the condensed | | $ 7,771 | | $ 10,515 | | | | |
| Supplemental disclosure of cash flow information | | | | | | | | |
| Cash paid for interest | | $ 893 | | $ 1,133 | | | | |
| Issuance of common stock upon conversion of debt in the current period | | $ 150 | | $ — | | | | |
| Restricted stock units issued to settle accrued bonus liabilities | | $ 212 | | $ — | | | | |
| Issuance of common stock relieving accrued settlement liabilities | | $ 102 | | $ — | | | | |
View original content to download multimedia:https://www.prnewswire.com/news-releases/marpai-reports-third-quarter-2026-financial-results-302938392.html
SOURCE